Jenny Jiang

ORCID: 0000-0003-0341-1385
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Atrial Fibrillation Management and Outcomes
  • Venous Thromboembolism Diagnosis and Management
  • Health Systems, Economic Evaluations, Quality of Life
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Cardiac Arrhythmias and Treatments
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Monoclonal and Polyclonal Antibodies Research
  • Acute Ischemic Stroke Management
  • Pharmaceutical Practices and Patient Outcomes
  • Medication Adherence and Compliance
  • COVID-19 Clinical Research Studies
  • Alzheimer's disease research and treatments
  • Neurological Disorders and Treatments
  • Cardiomyopathy and Myosin Studies
  • Long-Term Effects of COVID-19
  • Congenital Heart Disease Studies
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Acute Myocardial Infarction Research
  • Cholinesterase and Neurodegenerative Diseases
  • Neonatal Respiratory Health Research
  • Single-cell and spatial transcriptomics
  • T-cell and B-cell Immunology
  • COVID-19 and healthcare impacts

Bristol-Myers Squibb (United States)
2019-2025

Pfizer (United States)
2023-2024

University of Pennsylvania
2023-2024

Walgreens (United States)
2006-2018

Deerfield (United States)
2010-2018

The University of Texas MD Anderson Cancer Center
2018

Kaiser Permanente South San Francisco Medical Center
2012

National Patient Safety Foundation
2010

Cleveland Clinic
2010

Center for Drug Evaluation and Research
2010

Using data from the 2000-2004 US Healthcare Cost and Utilization Project National Inpatient Sample, we found that total hospital admissions for skin soft tissue infections increased by 29% during 2000-2004; pneumonia were largely unchanged. These results are consistent with recent reported increases in community-associated methicillin-resistant Staphylococcus aureus infections.

10.3201/eid1509.081228 article EN cc-by Emerging infectious diseases 2009-09-01

Atrial fibrillation (AF), a common heart rhythm abnormality, is linked to higher risk of stroke. Traditionally, warfarin has been the primary anticoagulation treatment for reducing stroke risk. The new standard by direct oral anticoagulants (DOACs) offers greater benefits including improved efficacy and fewer adverse effects with reduced monitoring. This study aims evaluate stroke/systemic embolism (SE) major bleeding (MB) among patients AF who switched from DOACs. utilized Medicare data...

10.1007/s12325-024-03099-y article EN cc-by-nc Advances in Therapy 2025-01-30

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies and inflammation in multiple organ systems. Elevation messenger RNA levels interferon (IFN)-regulated genes (IRGs) has been described peripheral blood SLE patients associated with activity. The safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) rontalizumab, humanized IgG1 monoclonal antibody that neutralizes IFNα, were assessed phase I dose-escalation study...

10.1002/art.34632 article EN Arthritis & Rheumatism 2012-07-25

The clinical success of the immune checkpoint inhibitor (ICI) targeting programmed cell death protein 1 (PD-1) has revolutionized cancer treatment. However, full potential PD-1 blockade therapy remains unrealized, as response rates are still low across many types. Interleukin-2 (IL-2)-based immunotherapies hold promise, they can stimulate robust T expansion and enhance effector function - activities that could synergize potently with blockade. Yet, IL-2 therapies also carry a significant...

10.3389/fimmu.2025.1537466 article EN cc-by Frontiers in Immunology 2025-02-18

Patients with cancer are more likely to develop nonvalvular atrial fibrillation (NVAF). Currently there no definitive clinical trials or treatment guidelines for NVAF patients concurrent cancer.This subgroup analysis of the ARISTOPHANES study compared risk stroke/systemic embolism (stroke/SE) and major bleeding (MB) among active who were prescribed non-vitamin K antagonist oral anticoagulants (NOACs) warfarin.A retrospective observational was conducted in newly initiated apixaban,...

10.1016/j.jaccao.2021.06.004 article EN cc-by-nc-nd JACC CardioOncology 2021-09-01

Abstract Targeting interactions between α4β7 integrin and endothelial adhesion molecule MAdCAM-1 to inhibit lymphocyte migration the gastrointestinal tract is an effective therapy in inflammatory bowel disease (IBD). Following entry into mucosa, a subset of these cells expresses αEβ7 integrin, which expressed on proinflammatory lymphocytes, increase cell retention. The factors governing intestinal mucosa αE expression healthy subjects IBD patients remain incompletely understood. We evaluated...

10.4049/jimmunol.2100220 article EN cc-by The Journal of Immunology 2021-09-24

<h3>Importance</h3> Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of gastrointestinal (GI) bleeding due to conditions including older age; stage III V chronic kidney disease (CKD); HAS-BLED (hypertension, or liver disease, stroke history, prior bleeding, unstable international normalized ratio, age &gt;65, drug alcohol use) score 3 greater; corticosteroid, antiplatelet nonsteroidal anti-inflammatory (NSAID) use; GI conditions. <h3>Objective</h3> To compare the...

10.1001/jamanetworkopen.2021.20064 article EN cc-by-nc-nd JAMA Network Open 2021-08-16

In addition to its anti-ischemic and antianginal effects, ranolazine has been shown lower hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) in patients with coronary artery disease diabetes. The present study was undertaken test the hypothesis that lowers HbA<sub>1c</sub> because of improved glucose homeostasis an animal model. Diabetes mice induced by giving multiple low doses streptozotocin. Ranolazine given twice daily via oral gavage (20 mg/kg) for 8 weeks. Fasting plasma levels were...

10.1124/jpet.110.176396 article EN Journal of Pharmacology and Experimental Therapeutics 2011-01-12

Background: Real-world evidence on direct oral anticoagulant outcomes among Non-Valvular Atrial Fibrillation (NVAF) patients is limited. We aimed to evaluate stroke/systemic embolism (SE) and major bleeding (MB) risks NVAF continuing or switching different anticoagulants. Methods: Using Optum’s de-identified Clinformatics® Data Mart Database, we identified initiating apixaban rivaroxaban between 1 January 2013 31 December 2021. Patients therapies within 30 days before 90 after discontinuing...

10.3390/jcm13041073 article EN Journal of Clinical Medicine 2024-02-14

Abstract Background The rate of cytomegalovirus (CMV) viral load increase and peak loads are associated with CMV disease in kidney liver transplant recipients, but relationships to severity or mortality have not been shown. Methods Using stored serial serum specimens from renal (n = 59) 35) recipients (D+R-; CMV-seropositive donors, CMV-seronegative recipients) 2 prospective, randomized, controlled, interventional prophylaxis trials immune globulin (CMVIG), was measured using the COBAS...

10.1093/ofid/ofz003 article EN cc-by-nc-nd Open Forum Infectious Diseases 2019-01-14

Gastrointestinal (GI) bleeding is the most common type of major associated with oral anticoagulant (OAC) treatment. Patients are at an increased risk a stroke if OAC not reinitiated.Non-valvular atrial fibrillation (NVAF) patients initiating OACs were identified from Centers for Medicare and Medicaid Services (CMS) data four US commercial claims databases. who had GI event (hospitalization primary diagnosis bleeding) while on selected. A control cohort without bleed during treatment was...

10.1177/1756284821997352 article EN cc-by-nc Therapeutic Advances in Gastroenterology 2021-01-01

Aims Assess the relationship between New York Heart Association (NYHA) functional class and cardiovascular (CV) outcomes in obstructive hypertrophic cardiomyopathy (HCM).

10.1080/13696998.2023.2277076 article EN Journal of Medical Economics 2023-10-30

Objectives: To assess the association between apixaban use and risk of stroke/systemic embolism (SE) major bleeding (MB) compared with other anticoagulants (OACs) across demographic socio-economic subgroups in treatment nonvalvular atrial fibrillation (NVAF). Methods: The study included adult NVAF patients initiating OAC 2013 2019 Medicare database. Inverse probability weighted Cox proportional hazard models were used to stroke/SE MB outcomes various subgroups. Results: Overall, adjusted...

10.3390/jcm14093252 article EN Journal of Clinical Medicine 2025-05-07

To investigate the relationship between two widely used, generic health-related quality of life (HRQOL) measures, Short Form-12 (SF-12) and EuroQol's EQ-5D, potentially inappropriate drug use in an elderly cohort.Longitudinal retrospective cohort study.Medical Expenditure Panel Survey, panel 5.Respondents aged 65 years or older.Participants with were identified by using National Drug Codes based on Beers updated criteria. The dependent variable, HRQOL, was measured self-reported scores SF-12...

10.1592/phco.26.6.768 article EN Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 2006-05-22

Thoracic outlet syndrome (TOS) is a neurovascular condition involving the upper extremity, which known to occur in individuals who perform chronic repetitive extremity activities. We prospectively evaluate incidence of TOS high-performance musicians played bowed string musicians. Sixty-four instrument from orchestras and professional musical bands were included study. Fifty-two healthy volunteers formed an age-matched control group. Bilateral duplex scanning for subclavian vessel compression...

10.3390/diagnostics8010011 article EN cc-by Diagnostics 2018-01-25

Drug development for systemic sclerosis (SSc) benefits from understanding the relationship between disease and circulating biomarkers to enable activities such as patient stratification evaluation of therapeutic response. We measured in serum SSc patients a phase 3 trial tocilizumab (focuSSced) compared baseline levels with healthy controls (HCs). Several appeared elevated HCs, suggesting activation epithelial damage, inflammation, fibrosis, extracellular matrix (ECM) remodeling. Baseline...

10.1016/j.clim.2023.109695 article EN cc-by-nc-nd Clinical Immunology 2023-07-20

We aimed to investigate the effect of male masturbator on prolonged masturbation duration in general population. 24 single men with normal erectile function participated this experiment. The entire protocol consisted a 4 weeks training using masturbator, corresponding time and round-trip frequency recorded vibration sensor. After training, average assisted increased from 6.00 ± 2.04 min 11.05 4.11 min, an increase about 5 compared that bare hands. However, hands before after has only...

10.56397/jimr/2025.02.04 article EN Journal of Innovations in Medical Research 2025-02-01

Antibody-Drug Conjugates (ADCs) are targeted cancer therapies delivering cytotoxic agents selectively to cells. Despite clinical success across various malignancies, resistance ADC therapy limits long-term efficacy. A key mechanism is inducing immunogenic cell death (ICD), releasing damage-associated molecular patterns (DAMPs) and tumor antigens stimulate an immune response. This provides a rationale for combining ADCs with immunotherapies overcome improve survival rates.AWT020 novel fusion...

10.1158/1538-7445.am2025-4774 article EN Cancer Research 2025-04-21

Modulating the binding affinities to IgE or changing FcγR properties of anti-IgE antibodies offers an opportunity enhance therapeutic potential antibodies, but influence increased affinity reduced Fc effector function on pharmacological therapies remains unclear. Our studies were designed characterize pharmacokinetics, pharmacodynamics and immune-complex distribution two high-affinity monoclonal antibody (HAE) 1 2, in mice monkeys. HAE1, also known as PRO98498, is structurally similar...

10.4161/mabs.22216 article EN mAbs 2012-11-01

Abstract Aims Polypharmacy is prevalent among non-valvular atrial fibrillation (NVAF) patients and presents a potential issue for the effective management of NVAF. This study compared risk stroke/systemic embolism (SE) major bleeding (MB) NVAF with polypharmacy newly prescribed oral anticoagulants (OACs). Methods results A retrospective who initiated OACs from 01 January 2013 to 30 September 2015 was conducted using US CMS Medicare four commercial databases. defined as ≥6 concomitant...

10.1093/ehjcvp/pvaa117 article EN European Heart Journal - Cardiovascular Pharmacotherapy 2020-09-18

Abstract Oral anticoagulants (OACs) have been used to prevent stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation (NVAF). To evaluate baseline clinical characteristics, incidence rates of stroke/SE and hospitalization for bleeding, OAC use elderly NVAF in the US by geographic region. Patients were selected from Centers Medicare &amp; Medicaid Services claims database (01JAN2013-31DEC2016). Twelve months health plan enrollment was required before after diagnosis...

10.1007/s11239-023-02855-1 article EN cc-by Journal of Thrombosis and Thrombolysis 2023-08-02
Coming Soon ...